Harmony Biosciences' Next CEO Gets A $725,000 Salary And $2.5 Million In Stock Awards
An amended filing sets Peter Anastasiou's pay as CEO and a $500-an-hour consulting deal for retiring chief Jeffrey Dayno.
Harmony Biosciences, the neuroscience drug company behind the narcolepsy treatment WAKIX, has now disclosed in an amended filing that incoming CEO Peter Anastasiou will earn a $725,000 base salary starting January 1, 2027. The 8-K/A, filed Friday, also lays out the exit terms for retiring CEO Jeffrey Dayno, who will stay on as a paid consultant.
Anastasiou's pay package
Anastasiou, now the company's Senior Executive Vice President and Chief Operating Officer, signed an amended and restated employment agreement on October 29. It takes effect when he becomes President and CEO and joins the board as a Class I director on January 1, 2027.
His target annual bonus, starting with calendar 2027, is 75% of base salary. Within 30 days of taking over, he is eligible for an option award with a grant date fair value of $1,750,000 and restricted stock units valued at $750,000.
Each award vests 25% on the first anniversary of the January 1, 2027 start date. The remaining 75% vests quarterly until the fourth anniversary, provided he is still serving at each vesting date.
Dayno's exit and consulting role
Dayno, who announced his retirement on October 12 as part of a succession plan, leaves as CEO and director at 11:59 p.m. Eastern Time on December 31, 2026. Under a separation and consulting agreement also dated October 29, he receives the severance and benefits already provided in his employment and award agreements. In exchange, he gives a release of claims and agrees to keep complying with the deal and any restrictive covenants.
He is expected to advise the company through January 31, 2028. For that work he is eligible for $500 per hour, and his existing equity awards keep vesting based on his continued service. They vest in full if a change in control occurs during the consulting period.
What the amendment fills in
The company said it filed the amendment to add compensation and separation arrangements that had not been determined when it filed its original 8-K on October 13. Nothing else in that report changed.
Harmony sells WAKIX, a once-daily tablet for excessive daytime sleepiness and cataplexy in narcolepsy, which brought in $868.5 million in net product revenue in 2025, according to its annual report.
Anastasiou takes the CEO seat at 12:00 a.m. Eastern Time on January 1, 2027, minutes after Dayno's departure takes effect.
Sources
- 8-K/A Filing (Amendment) — Harmony Biosciences Holdings, Inc. (HRMY) — SEC EDGAR
- Original 8-K — Harmony Biosciences Holdings, Inc. (filed 2026-10-13) — SEC EDGAR